Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374204 | 0.94 | CACNA1I (0.50) | CACNA1IKCNH2CACNA1HCACNA1GDPP4 | |
| SCHEMBL16478284 | 0.94 | CACNA1I (0.50) | CACNA1IKCNH2CACNA1HCACNA1GDPP4 | |
| SCHEMBL16478339 | 0.87 | KMT2A (0.48) | CACNA1IKCNH2CACNA1HCACNA1G | |
| SCHEMBL4280614 | 0.85 | CACNA1I (0.48) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL4280619 | 0.85 | CACNA1I (0.48) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL8371289 | 0.84 | CACNA1I (0.62) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL8374203 | 0.84 | CACNA1I (0.62) | CACNA1IKCNH2CACNA1HCACNA1GCYP2D6 | |
| SCHEMBL8371157 | 0.84 | CACNA1H (0.48) | CACNA1IKCNH2CACNA1HCACNA1GDPP4 | |
| SCHEMBL16478275 | 0.84 | CACNA1H (0.48) | CACNA1IKCNH2CACNA1HCACNA1GDPP4 | |
| SCHEMBL8371812 | 0.83 | DPP4 (0.56) | CACNA1IKCNH2CACNA1HCACNA1GDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.